Therapeutics News and Research

RSS

Common member of the gut microbiome found to have specific preference for blood group A antigens

Researchers have discovered that a common member of the human gut microbiome has a specific preference for blood group A antigens.

10 Jan 2022

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

A recent study uses an artificial intelligence model to investigate Omicron's mutations and its infectivity, vaccine escape capability, and susceptibility to monoclonal antibodies.

10 Jan 2022

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.

9 Jan 2022

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus vaccine candidate.

7 Jan 2022

Curia unveils comprehensive mRNA solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle formulation and development for full-scale sterile fill-finish services.

From Curia Global, Inc. 7 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

Research uncovers how a mouse brain understands sensory information

The brain is the most complex organ in our body – constantly absorbing and interpreting our surroundings, and guiding our movement, thoughts, behaviors and emotions.

6 Jan 2022

New approach with mRNA preparation reprograms T cells to attack heart fibroblasts

An experimental immunotherapy can temporarily reprogram patients' immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

6 Jan 2022

Researchers identify how a critical schistosomiasis drug works on the molecular level

Independent teams from Texas Biomedical Research Institute and the Medical College of Wisconsin have published two papers in Science Translational Medicine identifying how the only approved drug to treat schistosomiasis, a widespread parasitic worm infection, works on the molecular level.

6 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

How diet, supplements and lifestyle changes can help battle COVID

A recent editorial in the journal Nutrients emphasizes how efficacious non-pharmacological interventions in conjunction with the promotion of healthy lifestyle and dietary patterns may improve overall health status and reduce the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the potential adverse effects of coronavirus disease 2019 (COVID-19).

6 Jan 2022

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King's College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously.

4 Jan 2022

Therapeutics News and Research

Common member of the gut microbiome found to have specific preference for blood group A antigens

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Curia unveils comprehensive mRNA solution

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

Research uncovers how a mouse brain understands sensory information

New approach with mRNA preparation reprograms T cells to attack heart fibroblasts

Researchers identify how a critical schistosomiasis drug works on the molecular level

Small molecule identified as a SARS-CoV-2 inhibitor

How diet, supplements and lifestyle changes can help battle COVID

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

A closer look at the relationship between COVID-19 and Alzheimer’s disease

New Potocsnak Longevity Institute aims to extend human 'healthspan'

The impact of natural selection on sequence diversity in SARS-CoV-2

Computational tools reveal how blood enzyme works at the atomic level

Olfactory receptor gene may play a role in breast cancer metastasis to the brain

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News